A novel, cryopreserved, viable osteochondral allograft designed to augment marrow stimulation for articular cartilage repair
© Geraghty et al.; licensee BioMed Central. 2015
Received: 23 January 2015
Accepted: 6 April 2015
Published: 14 May 2015
Here, we describe the design and characterization of a novel, cryopreserved, viable osteochondral allograft (CVOCA), along with evidence that the CVOCA can improve outcomes of marrow stimulation for articular cartilage repair.
Histological staining was performed to evaluate the CVOCA tissue architecture. CVOCAs were tested for the presence of extracellular matrix (ECM) proteins and chondrogenic growth factors using ELISA. Cell viability and composition were examined via live/dead staining, fluorescence-activated cell sorting (FACS) analysis, and immunofluorescence staining. FACS analysis and a TNF-α secretion bioassay were used to confirm the lack of immunogenic cells. Effects of the CVOCA on mesenchymal stem cells (MSCs) were tested using in vitro migration and chondrogenesis assays. The ability of the CVOCA to augment marrow stimulation in vivo was evaluated in a goat model.
A method of tissue processing and preservation was developed resulting in a CVOCA with pores and minimal bone. The pores were found to increase the flexibility of the CVOCA and enhance growth factor release. Histological staining revealed that all three zones of hyaline cartilage were preserved within the CVOCA. Chondrogenic growth factors (TGF-β1, TGF-β3, BMP-2, BMP-4, BMP-7, bFGF, IGF-1) and ECM proteins (type II collagen, hyaluronan) were retained within the CVOCA, and their sustained release in culture was observed (TGF β1, TGF-β2, aggrecan). The cells within the CVOCA were confirmed to be chondrocytes and remained viable and functional post-thaw. Immunogenicity testing confirmed the absence of immunogenic cells. The CVOCA induced MSC migration and chondrogenesis in vitro. Experimental results using devitalized flash frozen osteochondral allografts revealed the importance of preserving all components of articular cartilage in the CVOCA. Goats treated with the CVOCA and marrow stimulation exhibited better repair compared to goats treated with marrow stimulation alone.
The CVOCA retains viable chondrocytes, chondrogenic growth factors, and ECM proteins within the intact architecture of native hyaline cartilage. The CVOCA promotes MSC migration and chondrogenesis following marrow stimulation, improving articular cartilage repair.
Articular cartilage damage is a common orthopedic problem, with more than 60 % of knee arthroscopies revealing chondral or osteochondral defects [1, 2]. The capacity for spontaneous articular cartilage repair is very limited [3–6]. Therefore, several surgical options have emerged to reduce pain and restore the structure and function of injured articular cartilage. Marrow stimulation, a reparative approach, and osteochondral allografts, a restorative approach, are commonly employed techniques.
Marrow stimulation is often employed following debridement to fill a lesion with repair tissue [5, 7]. In marrow stimulation, the subchondral bone is penetrated in order to introduce MSCs from the bone marrow into the lesion to generate repair tissue. The initial blood clot filling the lesion typically becomes fibrocartilage repair tissue, with less type II collagen and reduced mechanical integrity compared to normal, hyaline cartilage [8–10]. While marrow stimulation generally has good results in young patients (<40 years old) with small lesions (<2 cm2), the fibrocartilage often breaks down over time leading to poor long-term outcomes, especially in older patients and in lesions larger than 2 cm2 [8, 10–14]. Several adjuncts to marrow stimulation have recently been developed with the goal of directing the MSCs to become chondrocytes that produce hyaline cartilage. Various scaffolds, cells, and growth factors have been studied for this purpose, but their clinical benefits are not yet clearly defined.
Osteochondral allografting is a restorative procedure in which a cadaveric graft consisting of articular cartilage and its underlying subchondral bone is transplanted into the defect. Osteochondral allografts can be used to treat larger osteochondral lesions, but the procedure relies on precise instrumentation to match the size and contours of the donor tissue to the patient lesion. The clinical use of fresh and fresh stored osteochondral allografts began more than 40 years ago and has shown good results [7, 15]. As the implantation technique and selection criteria have improved, long-term clinical success rates have increased to 80–85 % on average, and above 95 % in more recent studies of knee defect repair [16–20]. Currently, fresh osteochondral allografts are stored at 4 °C in media for approximately 14 days while microbiological screening and recipient matching is completed and are typically used within 30 days, the time point when chondrocyte viability begins to decline significantly [21–24]. The short shelf life and size-matched donor availability limit the use of fresh stored osteochondral allografts. Frozen osteochondral allografts offer a longer shelf life, but they lose chondrocyte viability and have a higher likelihood of delaminating from the surrounding tissue [25, 26].
Here, we present a new option that combines reparative and restorative approaches for articular cartilage repair. The cryopreserved, viable osteochondral allograft (CVOCA) is a novel osteochondral allograft with only a minimal amount of bone and pores spanning the thickness of the allograft. The CVOCA builds upon more than 40 years of safety and efficacy of fresh stored osteochondral allografts as a restorative approach to articular cartilage repair. In contrast to fresh stored osteochondral allografts, the CVOCA can be stored frozen for up to 2 years, can fit to any surface contour, and can be implanted arthroscopically. In addition to increasing the flexibility of the CVOCA, the pores enable the cryopreservation solution to penetrate the tissue to preserve cell viability throughout rather than just at the surface, as seen in previous attempts at cartilage cryopreservation . When the CVOCA is used with marrow stimulation, MSCs released from the bone marrow will initiate a reparative response within the lesion in addition to the restorative approach from the allograft cartilage itself. The MSCs will be stimulated to undergo chondrogenesis within the pores of the CVOCA and produce type II collagen-rich hyaline repair tissue. In this study, we characterize the CVOCA and provide data supporting our hypothesis that the novel CVOCA can improve articular cartilage repair when used with marrow stimulation.
Tissue procurement and CVOCA preparation
Human knees en bloc from 18 to 60-year-old donors that were deemed as eligible for tissue donation for medical research were shipped on wet ice and processed within 120 h post-mortem. Osteochondral plugs (20 mm and 10 mm in diameter, 1 to 3 mm thick) were harvested from regions of healthy cartilage in the distal femur and proximal tibia. Most of the osseous portion of each plug was removed, leaving osteochondral allografts retaining the entire thickness of hyaline cartilage and residual subchondral bone. A score mark was added to the bone side of each osteochondral allograft to maintain directionality. Pores spanning the full thickness of the osteochondral allografts were created. The CVOCAs were cryopreserved in a DMSO-based solution using a controlled rate freezer (Cryomed Model 7454) and stored at —80 °C. When ready for testing, the CVOCAs were thawed in a 37 °C water bath and rinsed in saline.
In designing the CVOCA, the importance of the pores and their optimum size and density were investigated. Pore diameters of 0.6 and 0.9 mm and densities of 12, 25, and 50 pores/cm2 were tested for flexibility. Six blinded evaluators rated the flexibility of each CVOCA on a scale from 1 to 5 (1 = most flexible, 5 = least flexible). TGF-β1 release from the CVOCA (10-mm diameter size) with pores (1-mm diameter, 36 pores/cm2) and without pores after a 7 day culture (in Dulbecco's modified Eagle's medium (DMEM) with 10 % fetal bovine serum (FBS), 2 % Glutamax, 2 % antibiotic-antimycotic) was measured by ELISA (TGF-β1 Quantikine kit, R&D Systems, Minneapolis, MN, USA).
Histological characterization and immunostaining of CVOCA
The structure and extracellular matrix (ECM) contents of the CVOCA were investigated through histological staining of vertical cross sections. CVOCAs were fixed in 4 % paraformaldehyde, decalcified in 10 % formic acid, and embedded in paraffin. Serial 5-μm thick sections from the center of the CVOCA were stained with hematoxylin and eosin (H&E), safranin O, and antibodies for type I and type II collagen according to standard procedures. In negative control sections, normal rabbit serum was substituted for the primary antibody. Positive control sections included sections of normal human articular cartilage (for type II collagen) and subchondral bone (for type I collagen).
ELISA for ECM proteins in CVOCA
CVOCA tissue lysates and culture supernatants were analyzed using ELISAs for the presence of ECM proteins. CVOCAs were homogenized and the resulting tissue lysates were analyzed using ELISA kits for type II collagen (Astarte Biologics, Bothell, WA, USA) and hyaluronan (R&D Systems, Minneapolis, MN, USA) following the manufacturer’s protocols. CVOCAs were cultured with chondrocyte growth culture media (Lonza, Basel, Switzerland) at 37 °C and 5 % CO2. Media collected after 1, 3, 7, and 14 days was analyzed using an aggrecan ELISA kit (DIAsource ImmunoAssays, Louvain-la-Neuve, Belgium) following the manufacturer’s protocol.
ELISA for chondrogenic growth factors in CVOCA
Chondrogenic growth factors were evaluated in CVOCA tissue lysates using Quantikine and DuoSet ELISA kits (R&D Systems, Minneapolis, MN, USA) for TGF-β1, TGF-β3, BMP-2, BMP-4, BMP-7, bFGF, and IGF-1 following the manufacturer’s protocols. Culture supernatants were collected after 7, 14, and 21 days of CVOCA culture at 37 °C and 5 % CO2 in chondrocyte growth culture media (Lonza, Basel, Switzerland). The culture supernatants were analyzed using DuoSet ELISA kits (R&D Systems, Minneapolis, MN, USA) for TGF-β1, TGF-β2, bFGF, and IGF-1 following the manufacturer’s protocols. For comparison, the cells were devitalized in some samples by freeze-thawing the CVOCAs three consecutive times in a liquid nitrogen bath to create flash frozen OCAs before use in the culture.
Live/dead cell staining in CVOCA
Cell distribution and viability within the CVOCA were investigated using live/dead cell staining. A scalpel blade was used to cut thin horizontal tissue sections from the superficial end of the CVOCAs. The sections were incubated with a live/dead viability/cytotoxicity staining solution (Molecular Probes, Inc., Eugene, OR, USA) according to the manufacturer’s instructions. Stained sections were photographed under 100× magnification using a fluorescent microscope. Viable (green) and dead (red) cells within three random fields were counted within each of the CVOCA tissue sections. The counts from the three fields were averaged, and the percentage of viable cells was calculated for each CVOCA.
Isolation and analysis of cells from CVOCA
Cells were isolated by incubating minced CVOCAs with a pronase digestion media (70 U/ml, Sigma, St. Louis, Missouri, USA) for 1 h followed by a type I collagenase digestion media (300 U/ml, Sigma, St. Louis, Missouri, USA) for 3 h. Isolated cells were cultured in growth media (DMEM/Ham’s F-12 with 10 % FBS, 50 μg/ml ascorbic acid, 1 mg/ml glucose, and 0.2 % gentamicin) and passaged three to five times.
The cellular composition within the CVOCA was investigated through fluorescence-activated cell sorting (FACS). Cell suspensions were stained with phycoerythrin (PE)-labelled antibodies to CD44, CD45, CD49e, IgG1 (isotype control), or IgG2bκ (isotype control) (BD Biosciences, San Jose, CA, USA) according to standard procedures. The stained cells were evaluated using a single color analysis on a FACSCalibur system with CellQuest software (BD Biosciences, San Jose, CA, USA).
The cells isolated from the CVOCA were further characterized by immunostaining in culture for type II collagen and aggrecan according to standard protocols, with rabbit polyclonal anti-type II collagen and mouse monoclonal anti-aggrecan (Abcam, Cambridge, UK) used as the primary antibodies and Alexa Fluor 594 donkey anti-rabbit and Alexa Fluor 488 rabbit anti-mouse (Invitrogen, Grand Island, NY, USA) used as the secondary antibodies. Primary antibodies were not included into staining for negative control samples. All samples were stained with DAPI (Roche, Basel, Switzerland) and analyzed with a fluorescence microscope.
LPS-induced TNF-α secretion assay
Raw material (10-mm diameter osteochondral plugs with approximately 5 mm of bone) and fully processed CVOCAs (10-mm diameter) sourced from the same donor were cultured within wells of a 24-well plate in 2 ml of chondrocyte growth culture media (Lonza, Basel, Switzerland) per well. The samples were exposed to bacterial lipopolysaccharide (LPS) (1 μg/ml, Sigma, St. Louis, Missouri, USA) for 24 h at 37 °C. Human peripheral blood mononuclear cells (hPBMCs) cultured with LPS (2 × 106 cells/well) served as a positive control. Samples without LPS served as background controls. After the 24-h culture period, the media was collected and tested for the presence of TNF-α using a TNF-α DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol.
In vitro mesenchymal stem cell migration assay
A transwell filter system was utilized to measure the migration of MSCs towards media conditioned with CVOCAs or flash frozen OCAs. The CVOCAs and flash frozen OCAs (20-mm diameter) were cultured at 37 °C and 5 % CO2 in 3 ml of media (DMEM + 2 % antibiotic-antimycotic) for 7 days to create the conditioned media. DMEM was used as the negative control media while DMEM + 10 % FBS served as the positive control media. Six hundred microliters of the media was placed within wells of a 24-well plate. A 0.33-cm2 filter with 8-μm pores was added to each well so the media filled the well up to the filter. 1 × 105 human bone marrow-derived MSCs at passage 3–5 were seeded on the top of each filter. After a 4-h culture, the MSCs that did not migrate across the filters were removed from the top of each filter using cotton buds. The migrated MSCs were fixed and stained with a 4 % paraformaldehyde/1 % gentian violet solution. The migrated cells were visualized using light microscopy. The migrated cells were then removed from the bottom of each filter using 0.25 % trypsin-EDTA, spun down, resuspended in DMEM, and counted using a hemocytometer.
In vitro mesenchymal stem cell chondrogenesis assays
The ability of the CVOCA to induce MSC chondrogenesis was investigated using two in vitro CVOCA and MSC co-culture assays. First, MSC pellets were co-cultured with CVOCAs, but the two were not in direct contact. 2.5 × 105 human bone marrow-derived MSCs at passage 3–5 were pelleted into 15-ml conical tubes. A basal media (incomplete chondrogenic induction media, Lonza, Basel, Switzerland) was added to each tube. The basal media alone served as the negative control while the CVOCA (1/4 of 20-mm diameter CVOCA) was added to each experimental tube so it resided within the media but above the cell pellet for co-culture within the conical tube. After 3 weeks of culture, the pellets were sectioned and stained for type II collagen, using the standard protocol. The percentage of each pellet cross section that stained positive for type II collagen was calculated using ImageJ (US National Institutes of Health, Bethesda, Maryland, USA).
In order to mimic the in vivo microenvironment following microfracture and implantation of the CVOCA, a second in vitro chondrogenesis assay was performed where MSCs were suspended in fibrin glue and spread to fill the pores in the CVOCA with MSCs. Some of the CVOCAs were flash frozen in liquid nitrogen, as described previously. Each OCA (20-mm diameter) was placed in a well within a 24-well plate and 4 × 106 human bone marrow-derived MSCs at passage 3–5 in 100 μl of fibrin glue were spread over the CVOCA. One milliliter of complete or incomplete chondrogenic induction media (Lonza, Basel, Switzerland) was added to each well. After 4 weeks, the samples were sectioned vertically and horizontally and stained for type II collagen. The percentage of pore cross sections that stained positive for type II collagen was calculated using ImageJ (US National Institutes of Health, Bethesda, Maryland, USA).
CVOCA testing in a goat microfracture model
The CVOCAs were implanted in goats in order to demonstrate safety and to investigate the time course of integration following implantation. Approval was obtained from the Institutional Animal Care and Use Committee (IACUC) of Thomas D. Morris, Inc. for the use of animals in this study. Young (<1 year old) Spanish goat CVOCAs of 6-mm diameter were prepared using the same methods that were developed for human tissue processing. The goat CVOCAs were implanted in nine skeletally mature (2–4 years old), female Spanish goats. In each goat, two critical size cartilage defects (6 mm in diameter) were created in the medial femoral condyle of the right anterior knee joint using a biopsy punch and cartilage dissection tools. The defects in 3 goats (6 defects) were treated with marrow stimulation alone. The defects in the remaining 6 goats (12 defects) were treated with marrow stimulation augmented with the CVOCA. Following marrow stimulation, the CVOCA was secured in place by one of three methods: fibrin glue below and above the CVOCA (6 defects), fibrin glue above the CVOCA only (2 defects), or four 7-0 Vicryl sutures spaced evenly around the CVOCA and through the surrounding healthy cartilage (4 defects). The goats were fitted with a modified Thomas splint and cast immediately after surgery. The cast was removed after 21 days.
Repair tissue gross morphology scoring parameters. Parameters used to score goat repair tissue morphology. The total score was multiplied by the total percentage of defect fill to give the normalized grade score for each goat lesion
Test article or repair tissue presence in defect
Edge integration (new tissue relative to native cartilage)
Smoothness of the cartilage surface
Cartilage surface, degree of filling
Color of cartilage, opacity, or translucency of the neocartilage
Each experiment was run on CVOCAs from multiple donors. Data are presented as the mean ± standard error of the mean (SEM). Comparisons between groups were made using Student’s t-tests with significance at p < 0.05.
The pores were found to increase flexibility of the CVOCA and to enhance growth factor release from the CVOCA. The best flexibility score (2.2 ± 0.3) was assigned to CVOCAs with the large pore size (0.9 mm) at the highest density (50 pores/cm2). The worst flexibility score (4.8 ± 0.2) was assigned to CVOCAs with the small pore size (0.6 mm) at the lowest density (12 pores/cm2). The CVOCAs with the large pore size (0.9 mm) at the medium density (25 pores/cm2) were rated as the second most flexible (3.0 ± 0.4). Based on these results, 1-mm diameter pores at a density of 36 pores/cm2 were selected (Fig. 1). Following a 7-day culture, it was observed that CVOCAs with pores released more TGF-β1 than CVOCAs without pores (2,020 vs. 3,371 pg/ml). This boost may be attributed to the approximately 34 % overall increase in surface area that the 1-mm pores at 36 pores/cm2 provide.
Extracellular matrix content
Growth factor content
Many of the growth factors that are important for cartilage function, both in health and repair, were found to be present within the tissue and secreted by the CVOCA. Analysis of the CVOCA tissue lysates revealed that the CVOCA contained TGF-β1 and TGF-β3, two growth factors that promote chondrogenic differentiation of MSCs and regulate type II collagen expression in chondrocytes . The CVOCA tissue lysates contained BMP-2, BMP-4, and BMP-7. These bone morphogenetic proteins are capable of inducing MSC chondrogenesis and stimulating ECM production by chondrocytes . The CVOCA tissue lysates also contained bFGF, a growth factor that stimulates the proliferation of chondrocytes, and IGF-1, a growth factor that induces ECM synthesis in chondrocytes .
CVOCA-induced mesenchymal stem cell migration
CVOCA-induced mesenchymal stem cell chondrogenesis
CVOCA facilitated cartilage repair in a goat microfracture model
All goats remained clinically healthy and showed no local or systemic effects after the surgery. Upon examination after sacrifice, there was no evidence of infection or inflammation and synovial fluid appeared normal in all animals. Any degenerative changes between the operated and contralateral knee were generally matched for the medial femoral condyle, condyle groove junction, femoral groove, and proximal tibia and were not unusual for the animal’s age and species .
The Pineda histological scoring system addresses four parameters of cartilage repair quality with overall scores ranging from 0 for normal, healthy tissue to 14 for abnormal, damaged tissue . Pineda scores improved significantly for lesions treated with the CVOCA from 6.0 ± 0.8 at 3 months to 2.0 ± 0.6 at 12 months (p = 0.003). The reduction in Pineda scores over time was also significant for lesions treated with marrow stimulation alone (7.8 ± 0.7 at 3 months, 3.2 ± 0.2 at 12 months, p = 0.006). The scores for defect filling, one of the four parameters that make up the overall Pineda score, were significantly lower for the lesions treated with the CVOCA at both time points (p < 0.05). At 3 months, the scores for cell morphology, the measure of hyaline tissue in the Pineda system, were also significantly lower for lesions treated with the CVOCA (p = 0.04).
At the 3-month time point, when different methods for implanting the CVOCA were tested, all gross and histological scores were better when either fibrin glue above the CVOCA or sutures were used, rather than fibrin glue below and above the CVOCA. For this reason, it is recommended that the CVOCA is implanted in direct contact with the subchondral bone for clinical use.
In this study, we described the design and characteristics of a novel, cryopreserved, viable osteochondral allograft (CVOCA). Several goals were achieved in designing the CVOCA including flexibility, ease of use, a long storage time, and preservation of the structural matrix, growth factors, and viable chondrocytes. In addition, the CVOCA design allows it to be used in combination with marrow stimulation for articular cartilage repair.
Following a marrow stimulation procedure and implantation of the CVOCA, it is hypothesized that blood containing bone marrow MSCs will fill the pores of the CVOCA, forming stable clots within each pore. The growth factors released by the CVOCA will continue to recruit bone marrow MSCs towards the CVOCA over time. The CVOCA will not only serve as a scaffold for the MSCs, but the viable chondrocytes in the CVOCA will continually release growth factors into the surrounding microenvironment, influencing the MSCs to undergo chondrogenesis and produce hyaline repair tissue within the pores.
Over time, the reparative response initiated within the lesion is expected to not only fill in the pores of the CVOCA but also to integrate the border between the CVOCA and the host cartilage surrounding the defect. The residual bone in the CVOCA will help to anchor the allograft to the host bone through creeping substitution and re-vascularization, similar to the repair seen with traditional fresh stored osteochondral allografts [33, 34]. In this manner, the CVOCA is expected to result in a combination of allogeneic and autologous hyaline cartilage filling the lesion, strongly integrated with surrounding cartilage and underlying bone.
Here, we characterized the structure and contents of the CVOCA and provided in vitro and in vivo evidence supporting our hypothesis, demonstrating how the CVOCA works to augment marrow stimulation to improve articular cartilage repair. Histological staining revealed that the structure of the native hyaline cartilage is preserved and a thin layer of subchondral bone is present within the CVOCA. The CVOCA retains and secretes ECM proteins and growth factors that are typically found in hyaline cartilage. The CVOCA was non-immunogenic and contained viable chondrocytes that stained positive for aggrecan and type II collagen. Functionally, the CVOCA induces MSC migration and triggers MSC chondrogenesis. The highest level of chondrogenesis in vitro was seen when the MSCs were cultured within the pores of the CVOCA. These results support the hypothesis that the CVOCA can induce chondrogenesis of MSCs recruited from the bone marrow and trapped within the CVOCA pores following marrow stimulation, producing type II collagen and restoring damaged cartilage.
Including flash frozen OCAs, which do not contain viable chondrocytes, in some of our experiments revealed the importance of preserving all components of the CVOCA (ECM, growth factors, cells). The flash frozen OCA showed decreased growth factor release, MSC migration, and MSC chondrogenesis relative to the CVOCA with preserved living cells. These results indicate that viable chondrocytes continue to secrete growth factors, contributing to the persistence of growth factor secretion over time from the CVOCA and the resulting increase in MSC migration and chondrogenesis. The high percentage of viable cells preserved within the CVOCA (70.5 %) is a significant improvement compared to previous attempts at cartilage cryopreservation that resulted in only 20–50 % viable cells and, due to the known importance of viable cells for graft performance, prevented cryopreserved osteochondral allografts from gaining widespread use in the past [35–37].
The in vivo goat study further supports our hypothesis that the CVOCA improves repair compared to marrow stimulation alone. Defect filling and gross tissue appearance of lesions treated with marrow stimulation augmented with the CVOCA were superior (significantly higher normalized grade scores) to lesions treated with marrow stimulation alone at 3 months, suggesting that the CVOCA facilitates a faster repair than marrow stimulation alone. Histologically, the pores of the CVOCA were completely filled with highly cellular, type II collagen and proteoglycan-rich repair tissue at 3 months. By 12 months, gross and histological analyses showed integration of the implanted CVOCA with the host cartilage and bone. The goats treated with marrow stimulation alone had less lesion fill and zonal organization within the repair tissue. The study also demonstrated that the preferred fixation technique of the CVOCA is to suture or apply fibrin glue around the periphery or over the top of the CVOCA rather than at the base of the lesion. We hypothesize that the fibrin glue beneath the CVOCA reduces infiltration of host MSCs and inhibits integration with the subchondral bone and should therefore be avoided.
Our in vitro and in vivo data are validated by a recent clinical case . In this case study, the first documenting clinical use of the CVOCA, Hoffman et al. described a biopsy that was collected 9 months following implantation of the CVOCA in a 10-mm diameter trochlear defect. Histological staining of the biopsy showed 85 % hyaline cartilage repair tissue with strong type II collagen and proteoglycan staining, good cellularity, and a replicated tidemark. The pores of the CVOCA appeared filled upon inspection, and the patient reported resolution of pain and return to normal activity.
Clinically, the CVOCA has been used both as an adjunct to marrow stimulation and as a primary repair without deep marrow stimulation, more similar to a traditional osteochondral allograft. In the latter case, debridement of the cartilage and subchondral bone is performed until a bleeding bed is created within the lesion. The bleeding bed results in the formation of a blood clot that may help with integration of the implanted CVOCA. It is hypothesized that cartilage repair with the CVOCA will be mediated by the same mechanisms known for fresh stored osteochondral allografts. The CVOCA has a thin layer of bone which assists in integration with the patient’s own subchondral bone. However, the bone portion in the CVOCA was further reduced compared to fresh stored OCAs to enable the CVOCA to be flexible and to minimize damage to a patient’s healthy subchondral bone. Additional benefits to the CVOCA compared to fresh stored osteochondral allografts include a longer shelf life and no requirement for donor matching.
A novel cryopreserved viable osteochondral allograft (CVOCA), with pores and a reduced bone portion compared with a traditional osteochondral allograft, has been developed. The CVOCA maintains the structure and contents of native hyaline cartilage (ECM, growth factors, chondrocytes). This CVOCA induces MSC migration and chondrogenesis that can improve repair following a bone marrow stimulation procedure. Unique attributes of the CVOCA include its flexibility to fit defects of any shape and contour, a straightforward implantation technique, and a long shelf life that enables point of care use within a single surgery.
We thank Timothy Simon, Harold Aberman, and Dennis Kunishima (Applied Biological Concepts, Inc.) for performing surgery and collecting data in the goat study. We thank Premier Laboratory, LLC for performing all histological staining.
- Curl WW, Krome J, Gordon ES, Rushing J, Smith BP, Poehling GG. Cartilage injuries: a review of 31,516 knee arthroscopies. Arthroscopy. 1997;13(4):456–60.View ArticlePubMedGoogle Scholar
- Hjelle K, Solheim E, Strand T, Muri R, Brittberg M. Articular cartilage defects in 1,000 knee arthroscopies. Arthroscopy. 2002;18(7):730–4.View ArticlePubMedGoogle Scholar
- Buckwalter JA, Mankin HJ. Articular cartilage 2. Degeneration and osteoarthrosis, repair, regeneration, and transplantation. J Bone Joint Surg Am Vol. 1997;79A(4):612–32.Google Scholar
- Mandelbaum BR, Browne JE, Fu F, Micheli L, Mosely JB, Erggelet C, et al. Articular cartilage lesions of the knee. Am J Sports Med. 1998;26(6):853–61.PubMedGoogle Scholar
- Hunziker EB. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthr Cartil. 2002;10(6):432–63.View ArticlePubMedGoogle Scholar
- Vangsness Jr CT, Kurzweil PR, Lieberman JR. Restoring articular cartilage in the knee. Am J Orthop. 2004;33(2 Suppl):29–34.PubMedGoogle Scholar
- Bedi A, Feeley BT, Williams RJ. Management of articular cartilage defects of the knee. J Bone Joint Surg Am. 2010;92(4):994–1009.View ArticlePubMedGoogle Scholar
- Furukawa T, Eyre DR, Koide S, Glimcher MJ. Biochemical studies on repair cartilage resurfacing experimental defects in the rabbit knee. J Bone Joint Surg Am Vol. 1980;62(1):79–89.Google Scholar
- Breinan HA, Martin SD, Hsu HP, Spector M. Healing of canine articular cartilage defects treated with microfracture, a type-II collagen matrix, or cultured autologous chondrocytes. J Orthop Res. 2000;18(5):781–9.View ArticlePubMedGoogle Scholar
- Xing LZ, Jiang YQ, Gui JC, Lu YM, Gao F, Xu Y. Microfracture combined with osteochondral paste implantation was more effective than microfracture alone for full-thickness cartilage repair. Knee Surg Sports Traumatol Arthrosc. 2013;21(8):1770–6.View ArticlePubMedGoogle Scholar
- Steadman JR, Rodkey WG, Singleton SB, Briggs KK. Microfracture technique for full-thickness chondral defects: technique and clinical results. Oper Tech Orthop. 1997;7(4):300–4.View ArticleGoogle Scholar
- Cole BJ, Cohen B. Chondral injuries of the knee: a contemporary view of cartilage restoration. Orthopedics Special Ed. 2000;6:71–6.Google Scholar
- Mithoefer K, Williams RJ, Warren RF, Wickiewicz TL, Marx RG. High-impact athletics after knee articular cartilage repair—a prospective evaluation of the microfracture technique. Am J Sports Med. 2006;34(9):1413–8.View ArticlePubMedGoogle Scholar
- Kreuz PC, Erggelet C, Steinwachs MR, Krause SJ, Lahm A, Niemeyer P, et al. Is microfracture of chondral defects in the knee associated with different results in patients aged 40 years or younger? Arthroscopy. 2006;22(11):1180–6.View ArticlePubMedGoogle Scholar
- Gortz S, Bugbee W. Allografts in articular cartilage repair. J Bone Joint Surg Am Vol. 2006;88:1374–84.Google Scholar
- Gortz S, Bugbee WD. Fresh osteochondral allografts: graft processing and clinical applications. J Knee Surg. 2006;19(3):231–40.PubMedGoogle Scholar
- Demange M, Gomoll A. The use of osteochondral allografts in the management of cartilage defects. Curr Rev Musculoskelet Med. 2012;5:229–35.View ArticlePubMed CentralPubMedGoogle Scholar
- Winters BS, Raikin SM. The use of allograft in joint-preserving surgery for ankle osteochondral lesions and osteoarthritis. Foot Ankle Clin. 2013;18(3):529–42.View ArticlePubMedGoogle Scholar
- McCulloch PC, Kang RW, Sobhy MH, Hayden JK, Cole BJ. Prospective evaluation of prolonged fresh osteochondral allograft transplantation of the femoral condyle: minimum 2-year follow-up. Am J Sports Med. 2007;35(3):411–20.View ArticlePubMedGoogle Scholar
- LaPrade RF, Botker J, Herzog M, Agel J. Refrigerated osteoarticular allografts to treat articular cartilage defects of the femoral condyles. A prospective outcomes study. J Bone Joint Surg Am. 2009;91(4):805–11.View ArticlePubMedGoogle Scholar
- Langer F, Gross AE. Immunogenicity of allograft articular cartilage. J Bone Joint Surg Am. 1974;56(2):297–304.PubMedGoogle Scholar
- Allen RT, Robertson CM, Pennock AT, Bugbee WD, Harwood FL, Wong VW, et al. Analysis of stored osteochondral allografts at the time of surgical implantation. Am J Sports Med. 2005;33(10):1479–84.View ArticlePubMedGoogle Scholar
- Pearsall AW, Tucker JA, Hester RB, Heitman RJ. Chondrocyte viability in refrigerated osteochondral allografts used for transplantation within the knee. Am J Sports Med. 2004;32(1):125–31.View ArticlePubMedGoogle Scholar
- Williams 3rd RJ, Dreese JC, Chen CT. Chondrocyte survival and material properties of hypothermically stored cartilage: an evaluation of tissue used for osteochondral allograft transplantation. Am J Sports Med. 2004;32(1):132–9.View ArticlePubMedGoogle Scholar
- Enneking WF, Mindell ER. Observations on massive retrieved human allografts. J Bone Joint Surg Am. 1991;73(8):1123–42.PubMedGoogle Scholar
- Enneking WF, Campanacci DA. Retrieved human allografts: a clinicopathological study. J Bone Joint Surg Am. 2001;971–86.Google Scholar
- Ohlendorf C, Tomford WW, Mankin HJ. Chondrocyte survival in cryopreserved osteochondral articular cartilage. J Orthopaedic Res. 1996;14(3):413–6.View ArticleGoogle Scholar
- Pineda S, Pollack A, Stevenson S, Goldberg V, Caplan A. A semiquantitative scale for histologic grading of articular cartilage repair. Acta Anat. 1992;143(4):335–40.View ArticlePubMedGoogle Scholar
- Fortier LA, Barker JU, Strauss EJ, McCarrel TM, Cole BJ. The role of growth factors in cartilage repair. Clin Orthop Relat Res. 2011;469(10):2706–15.View ArticlePubMed CentralPubMedGoogle Scholar
- Grogan SP, Barbero A, Diaz-Romero J, Cleton-Jansen AM, Soeder S, Whiteside R, et al. Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity. Arthritis Rheum. 2007;56(2):586–95.View ArticlePubMedGoogle Scholar
- Diaz-Romero J, Gaillard JP, Grogan SP, Nesic D, Trub T, Mainil-Varlet P. Immunophenotypic analysis of human articular chondrocytes: changes in surface markers associated with cell expansion in monolayer culture. J Cell Physiol. 2005;202(3):731–42.View ArticlePubMedGoogle Scholar
- Jackson DW, Lalor PA, Aberman HM, Simon TM. Spontaneous repair of full-thickness defects of articular cartilage in a goat model. A preliminary study. J Bone Joint Surg Am. 2001;53–64.Google Scholar
- Bauer TW, Muschler GF. Bone graft materials. An overview of the basic science. Clin Orthop Relat Res. 2000;371:10–27.View ArticlePubMedGoogle Scholar
- Bugbee WD, Convery FR. Osteochondral allograft transplantation. Clin Sports Med. 1999;18(1):67–75.View ArticlePubMedGoogle Scholar
- Csonge L, Bravo D, Newman-Gage H, Rigley T, Conrad EU, Bakay A, et al. Banking of osteochondral allografts. Part II. Preservation of chondrocyte viability during long-term storage. Cell Tissue Bank. 2002;3(3):161–8.View ArticlePubMedGoogle Scholar
- Bakay A, Csonge L, Papp G, Fekete L. Osteochondral resurfacing of the knee joint with allograft. Clinical analysis of 33 cases. Int Orthop. 1998;22(5):277–81.View ArticlePubMed CentralPubMedGoogle Scholar
- Schachar NS, Novak K, Hurtig M, Muldrew K, McPherson R, Wohl G, et al. Transplantation of cryopreserved osteochondral Dowel allografts for repair of focal articular defects in an ovine model. J Orthopaedic Res. 1999;17(6):909–19.View ArticleGoogle Scholar
- Hoffman JK, Geraghty S, Protzman NM. Articular cartilage repair using marrow stimulation augmented with a viable chondral allograft: 9-month postoperative histological evaluation. Case Rep Orthopedics. 2015;2015(617365):10.Google Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.